Clinical Trials List
Protocol Number20180146
Active
2021-04-01 - 2028-12-31
Phase I
Recruiting2
-
Trial Applicant
IQVIA RDS Taiwan Ltd.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- 黃文冠 Division of Hematology & Oncology
- Po-Jung Su Division of Hematology & Oncology
- 張境夫 Division of Hematology & Oncology
- Jing-Ren Tseng Division of Nuclear Medicine
- Kai-Jie Yu Division of Hematology & Oncology
- Yuan-Cheng Chu Division of Hematology & Oncology
- I-hung Shao Division of Hematology & Oncology
- See-Tong Pang Division of Hematology & Oncology
- Feng-Yuan Liu Division of Nuclear Medicine
- 沈鼎文 Division of Radiology
- Ming-Mo Hou Division of Hematology & Oncology
- Rita cheng Division of Hematology & Oncology
- 黃亮鋼 Division of Hematology & Oncology
- Hong-Cheng Gan Division of Hematology & Oncology
- PO-HUNG LIN Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 徐偉勛 無
- CHING-CHU LU 無
- Jih-Hsiang Lee 無
- CHUNG-HSIN CHEN 無
- Yu-Chieh Tsai 無
- - - 無
- FU-JEN HSUEH 無
- 吳宗哲 無
- JHE-CYUAN GUO 無
- Yeong-Shiau Pu 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
40 participants
-
Global
470 participants
